Aktis Oncology, Inc. (AKTS) Q4 2023 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Aktis Oncology, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.029 -- 00:00:04.950 Good day, ladies and gentlemen, and welcome to the Acoustis Technologies Fiscal 2023 00:00:04.950 -- 00:00:07.391 Fourth Quarter Conference Call. 00:00:07.391 -- 00:00:10.692 As a reminder, this conference call is being recorded. 00:00:10.692 -- 00:00:15.254 At the conclusion of the company's presentation, Acoustis Management will take questions. 00:00:15.254 -- 00:00:20.815 To ask a question, please press star 1 on your telephone keypad to be placed in the queue. 00:00:20.815 -- 00:00:24.856 A replay of the call will be available on the Investor Relations section of the Acoustis 00:00:24.856 -- 00:00:26.717 website. 00:00:26.717 -- 00:00:31.198 I would now like to turn the floor over to Tom Sapenzis. 00:00:31.667 -- 00:00:34.849 Thank you, Operator, and good morning to everyone on the call. 00:00:34.849 -- 00:00:39.491 Welcome to ACOUSTA's fourth quarter fiscal 2023 conference call. 00:00:39.491 -- 00:00:44.614 We are joined today by our founder and CEO, Jeff Scheele, CFO Ken Bowler, 00:00:44.614 -- 00:00:48.076 and EVP of Business Development, Dave Eichle. 00:00:48.076 -- 00:00:52.999 Before we begin, please note that today's presentation includes forward-looking statements 00:00:52.999 -- 00:00:57.601 about our business outlook. All statements other than statements of historical facts 00:00:57.601 -- 00:01:03.387 included in this conference call such as expectations regarding our strategies and operations, 00:01:03.387 -- 00:01:08.330 including the timing and prospects of product development and customer orders and design 00:01:08.330 -- 00:01:13.873 wins, possible collaborative or partnering relationships, litigation matters, 00:01:13.873 -- 00:01:18.536 and expected financial and operating results, are forward-looking statemen...